New Prostate Cancer Radiotherapy Course Shows Less Side Effects, Treatment Time, Cost

New Prostate Cancer Radiotherapy Course Shows Less Side Effects, Treatment Time, Cost
UK researchers proved that a  hypofractionated high-dose intensity-modulated radiotherapy compared to conventional radiotherapy for prostate cancer, significantly impacts patient treatment time and outcome, and will save tens of millions in cost for the the National Health Service (NHS). "Our study shows that fewer, larger doses of intensity-modulated radiotherapy work just as well as more, smaller doses for men with prostate cancer, without reducing quality of life - and would save each man the inconvenience of 17 more hospital visits," said lead investigator  David Dearnaley, Professor of Uro-Oncology at The Institute of Cancer Research, London, and Consultant Clinical Oncologist at The Royal Marsden, said in a press release. A similar therapy regimen used in  breast cancer treatment since 2009 has so far saved the NHS 50 million euro per year. The new treatment for prostate cancer reduce hospital visits in the U.K. by 150,000 visits per year. The study, “Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomized, non-inferiority, phase 3 CHHiP trial,” was published in The Lancet Oncology. Several methods exist for the treatment of prostate cancer, including radiotherapy (also called radiation therapy) which exposes tumor cells to ionizing radiation to induce DNA damage and suppress cancerous t
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *